Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.

: Cytokine release syndrome plays a crucial pathogenic role in COVID-19 pneumonia. This pilot study provides the first evidence of the safety of anti-IL-1 treatment with highdose IV anakinra in 5 patients, who experienced a positive outcome.